Genetically engineered drugs like Xolair cost as much as $20,000 a year and cause TB, cancers and super infections because they suppress the immune system. But they seem slated to be the next big thing in asthma.
A study in May says Xolair can provide, "additional clinical benefit" for patients who are "inadequately controlled" on inhaled corticosteroids. That's exactly how Advair, Singulair and the other blockbuster asthma drugs were sold . The study was funded by Xolair's manufacturer and co-written by William Busse, who headed the government's National Asthma Education and Prevention Program Guidelines.
The first part of this series appears here
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
